11月17日,曼恩凯德生物医疗(MNKD.US)公布财报,公告显示公司2024财年第三财季净利润为11.55百万美元,同比增加571.51%;其中营业收入为70.08百万美元,同比增加36.74%,每股基本收益为0.04美元。从资产负债表来看,曼恩凯德生物医疗(MNKD.US)总负债6.74亿美元,其中短期债务13.07百万美元,资产负债比为0.69,流动比率为0.05。机构评级:截至2024年...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.